Oncor gets additional export approvals:
This article was originally published in Clinica
Executive Summary
The US FDA has given Oncor (US) permission to export its investigational IVD genetic test systems for HER-2/neu and Chronic Myelogenous Leukaemia Mbcrlabl to Austria, Switzerland and Ireland. This follows export approvals granted earlier this year (see Clinica No 661, p 17). Oncor expects its HER-2/neu (ERBB2) gene amplification detection system for breast cancer to be reviewed by a US FDA panel in the final quarter this year. A PMA application was filed for the test in February 1994.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.